Trilogy Sciences is developing mechanisms to enable reproducible engineering of breakthrough covalent drugs.
Triology Sceinces is a platform for creating breakthrough covalent drugs. Currently, the best-performing drugs (penicillin, aspirin) in the market are covalent. Covalent drugs utilize a highly beneficial mechanism of action with pharmacological advantages including enhanced potency, selectivity and prolonged duration of action. Yet, covalent drugs only represent 2% of the market because they tend to be found by accident.
Using game-changing technology, Trilogy’s platform allows for the broad design of covalent drugs. The company has targeted cancer treatments first, and could potentially enable the transformation of any drug to be covalent.